Authors
Latest:
Exciting Developments in the Pipeline in HER2+ MBCA multidisciplinary panel of health care professionals and a patient advocate comment on their excitement about novel therapies in the pipeline for HER2-positive metastatic breast cancer.
Latest:
Biomarkers for Response to Anti–PD-1/Anti–PD-L1 Immune Checkpoint Inhibitors: A Large Meta-AnalysisArshiya Mariam, BS, and colleagues report the findings of a large meta-analysis assessing the ability of various biomarkers to predict responses to immune checkpoint inhibition.
Latest:
Cancer Network Faceoff: Conclusion of the Event and Presentation of AwardFinal remarks and presentation of awards.
Latest:
Clinical Pearls about the Referral Process of Bispecifics and CAR-T in RRMMThe discussion shares key takeaways and practical insights for optimizing the referral and treatment process for CAR T-cell and bispecific therapies.
Latest:
Opsoclonus-Myoclonus–Associated Neuroblastoma With Bone Marrow Metastases: What Would Be the Best Treatment Option?In this clinical quandary, investigators determine how to best treat patients with opsoclonus-myoclonus–associated neuroblastoma with bone marrow metastases.
Latest:
Thoracic Oncologist Perspectives on a Rapidly Evolving Treatment LandscapePanelists discuss how thoracic oncologists are adapting to a rapidly evolving treatment landscape for lung cancer, focusing on the integration of novel therapies and the importance of biomarker-driven approaches in patient care.
Latest:
Treatment of Multiple Myeloma: Q&A Session With Yale Cancer Center and SatellitesA Q&A session with the expert panel.
Latest:
Marshall Posner, MD, on the Promise of Personalized mRNA Vaccines in Solid MalignanciesMarshall Posner, MD, detailed the potential for personalized mRNA vaccines to treat patients with various different tumors and what information is still needed.
Latest:
Ongoing Trials May Elucidate Mosunetuzumab Efficacy in Follicular LymphomaInvestigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.
Latest:
“Promising” Data Support Blinatumomab in CD19+ B-ALL PopulationOverall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.
Latest:
Alison M. Schram, MD, Reviews Data of Zenocutuzumab in the Phase 2 eNRGy Trial for NRG1 Fusion–Positive CancersAlison M. Schram, MD, spoke about key findings from the phase 2 eNRGy trial assessing zenocutuzumab in patients with NRG1 fusion–positive advanced solid tumors.
Latest:
Hereditary Renal Tumor Syndromes and the Use of mTOR InhibitorsA 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest pain. Upon admission, her oxygen saturation was 88%.
Latest:
Integrative Oncology in Young Women With Breast CancerYancey Warren, Jr, MD, MAT, and colleagues investigate the use of integrative oncology services among young women with breast cancer.
Latest:
Clinical Scenario: AE Management for Bispecific Therapy in R/R MMFollowing the review of a case of a patient with relapsed/refractory multiple myeloma, the panel provides expert perspectives on adverse event management practices.
